Atreca announces agreement with Zymeworks and selection of new clinical candidate April 6, 2022 No Comments
Guangzhou Maxinovel Pharmaceuticals discloses PD-1/PD-L1 interaction inhibitors April 5, 2022 No Comments
RSS